Progress of targeted therapy in Her-2 positive gastric cancer
10.11904/j.issn.1002-3070.2015.02.020
- VernacularTitle:H er －2阳性胃癌靶向治疗的研究进展
- Author:
Sen LI
;
Zhiguo LI
;
Long CHENG
;
Yingwei XUE
- Publication Type:Journal Article
- Keywords:
Gastric cancer;
Her-2;
Targeted therapy
- From:
Practical Oncology Journal
2015;(2):188-192
- CountryChina
- Language:Chinese
-
Abstract:
Although chemotherapy is an effective way for advanced gastric cancer ,it does not significant-ly improve the prognosis of patients .Recently ,further researches on the mechanism of gastric cancer have led to the identification of ′driver gene′and the development of new agents that target these genes .By inhibiting the hu-man epidermal growth factor receptor 2(Her-2)for advanced gastric cancer ,it provides a new treatment for pa-tients.Trastuzumab is a kind of Her -2 monoclonal antibody ,it is the first kind of targeted therapy drug for the treatment of advanced and metastatic gastric cancer .A combination of trastuzumab with cisplatin and fluorouracil based chemotherapy can benefit patients overall survival .Therefore,in this paper,we make a review and summary of a set of recent studies related to the gastric targeted therapy .
